1. Home
  2. MLYS vs FUL Comparison

MLYS vs FUL Comparison

Compare MLYS & FUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • FUL
  • Stock Information
  • Founded
  • MLYS 2019
  • FUL 1887
  • Country
  • MLYS United States
  • FUL United States
  • Employees
  • MLYS N/A
  • FUL N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • FUL Home Furnishings
  • Sector
  • MLYS Health Care
  • FUL Industrials
  • Exchange
  • MLYS Nasdaq
  • FUL Nasdaq
  • Market Cap
  • MLYS 3.1B
  • FUL 3.2B
  • IPO Year
  • MLYS 2023
  • FUL N/A
  • Fundamental
  • Price
  • MLYS $40.00
  • FUL $61.52
  • Analyst Decision
  • MLYS Strong Buy
  • FUL Strong Buy
  • Analyst Count
  • MLYS 6
  • FUL 5
  • Target Price
  • MLYS $42.60
  • FUL $70.20
  • AVG Volume (30 Days)
  • MLYS 1.3M
  • FUL 356.9K
  • Earning Date
  • MLYS 11-10-2025
  • FUL 09-24-2025
  • Dividend Yield
  • MLYS N/A
  • FUL 1.53%
  • EPS Growth
  • MLYS N/A
  • FUL N/A
  • EPS
  • MLYS N/A
  • FUL 2.07
  • Revenue
  • MLYS N/A
  • FUL $3,502,085,000.00
  • Revenue This Year
  • MLYS N/A
  • FUL N/A
  • Revenue Next Year
  • MLYS N/A
  • FUL $2.42
  • P/E Ratio
  • MLYS N/A
  • FUL $29.77
  • Revenue Growth
  • MLYS N/A
  • FUL N/A
  • 52 Week Low
  • MLYS $8.24
  • FUL $47.56
  • 52 Week High
  • MLYS $44.80
  • FUL $80.15
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 53.93
  • FUL 59.21
  • Support Level
  • MLYS $41.74
  • FUL $58.78
  • Resistance Level
  • MLYS $44.60
  • FUL $61.99
  • Average True Range (ATR)
  • MLYS 2.22
  • FUL 1.56
  • MACD
  • MLYS -0.83
  • FUL 0.34
  • Stochastic Oscillator
  • MLYS 46.44
  • FUL 90.41

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About FUL H. B. Fuller Company

H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.

Share on Social Networks: